Prostatic embolization as an alternative treatment for benign prostatic hyperplasia
DOI:
https://doi.org/10.35381/s.v.v6i3.2266Keywords:
prostatic hyperplasia, therapeutic methods, urological diseases. (Source, DeCS).Abstract
Objective: To present prostatic embolization as a treatment for benign prostatic hyperplasia through a literature review. Method: A systematic bibliographic review of different scientific documents was carried out in databases such as PubMed, SciELO, Elsevier, Cochrane, NCBI. Results and conclusions: Currently, prostate embolization has been proposed as a treatment for BPH. Several preclinical experimental studies have shown that this treatment is safe, since it does not cause erectile dysfunction and reduces prostate volume. It was possible to review several therapeutic methods, predominantly prostate embolization as the non-invasive surgical method of choice, offering a new cheaper therapeutic alternative, lower rate of recurrence of surgery and even lower risk of erectile dysfunction and increases the score of the parameters used for to measure the clinical evolution of the therapeutic treatment of BPH together with its efficacy.
Downloads
References
Kisilevzky N, Mónaco RG, Paralta O, Rabelino M, Arroba RR, Rodríguez P, et al. Embolización prostática: Un nuevo campo de actuación de la radiología intervencionista. [Prostatic embolization: A new field of action for interventional radiology]. Rev Argentina Radiol. 2014;78(2):102–13.
Garraway WM, Lee RJ, Collins GN. High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991 Aug 24;338(8765):469–71.
Eckhardt MD, Van Venrooij GEPM, Van Melick HHE, Boon TA. Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well-being. J Urol. 2001 Aug 1;166(2):563–8.
Rosen RC, Giuliano F, Carson CC. Sexual Dysfunction and Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH). Eur Urol. 2005 Jun 1;47(6):824–37.
Madersbacher S, Sampson N, Culig Z. Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review. Gerontology. 2019;65(5):458–64. https://n9.cl/sw431
Luque Zurita D, Pérez Valverde Á, Lizárraga Vargas L, Campos Beltrán S, Lazo Neira P. Epidemiologia de la Hiperplasia Prostatica Benigna (BPH).[ Epidemiology of Benign Prostatic Hyperplasia]. Scientiarvm. 2015 Jul 4;1(1):27–34.
Hiperplasia benigna de próstata: Visión general - Atención Primaria. [Benign Prostatic Hyperplasia: Overview - Primary Care] 2022. https://n9.cl/06cz3
Universidad Regional Autónoma de Los Andes “UNIANDES” Facultad de Ciencias Médicas Carrera de Medicina. (Proyecto de Investigación previo a la Obtención del título de médico cirujano). Prevalencia De La Hiperplasia Prostática Benigna. [Prevalence of Benign Prostatic Hyperplasia].
Noroña Vásconez EF, Vargas Páez CP. Comparación de los resultados clínicos en pacientes con hiperplasia prostática benigna con tratamiento inicial farmacológico, no farmacológico y quirúrgico, atendidos en el Hospital Pablo Arturo Suárez de enero 2014 a diciembre 2016. [Comparison of the clinical results in patients with benign prostatic hyperplasia with initial pharmacological, non-pharmacological and surgical treatment, treated at the Pablo Arturo Suárez Hospital from January 2014 to December 2016].QUITO. 2018;7(2):44–68.
Kim EH, Larson JA, Andriole GL. Management of benign prostatic hyperplasia. Annu Rev Med. 2016;67:137–51.
Lanciego C. Embolización prostática en HBP: “Indolora y no deja secuelas” [Prostatic embolization in BPH: "Painless and leaves no sequelae"]. https://n9.cl/0we54
Humberto Chiang M, Ricardo Susaeta C, Finsterbusch C. Síntomas urinarios bajos, prostatismo, hiperplasia prostática, uropatía obstructiva baja, ¿todo una misma cosa? [ Lower urinary symptoms, prostatism, prostatic hyperplasia, lower obstructive uropathy, all the same thing?].Rev Médica Clínica Las Condes. 2014 Jan 1;25(1):149–57.
Published
How to Cite
Issue
Section
License
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
OAI-PMH: https://fundacionkoinonia.com.ve/ojs/index.php/saludyvida/oai.
